Zentalis Pharmaceuticals, Inc. (ZNTL) Stock
ZNTL Key Statistics
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
CEO: Julie Eastland. Company website
ZNTL — Frequently Asked Questions
What is the ZNTL stock price today?
Zentalis Pharmaceuticals, Inc. (ZNTL) trades at $6.61, up 49.55% on the day, as of Sep 20, 2026 15:01 UTC.
What is Zentalis Pharmaceuticals, Inc.'s market cap?
Zentalis Pharmaceuticals, Inc. has a market capitalisation of $468.85M, calculated from the live ZNTL share price and shares outstanding.
What is the P/E ratio of ZNTL?
ZNTL has no meaningful price-to-earnings ratio: Zentalis Pharmaceuticals, Inc. lost $1.90 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Zentalis Pharmaceuticals, Inc. make?
Zentalis Pharmaceuticals, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for ZNTL?
ZNTL has traded between $2.07 and $6.95 over the past 52 weeks, and the last price is 4.9% below that high.
Is Zentalis Pharmaceuticals, Inc. profitable?
Yes. Zentalis Pharmaceuticals, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for ZNTL?
Wall Street analysts rate ZNTL Buy, with an average price target of $6.00, 9.2% below the current price.
What sector is Zentalis Pharmaceuticals, Inc. in?
Zentalis Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Zentalis Pharmaceuticals, Inc.?
Julie Eastland is the chief executive of Zentalis Pharmaceuticals, Inc., which employs 166 people.
Where can I track ZNTL in real time?
QFI Terminal shows ZNTL with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ZNTL live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ZNTL in Terminal See plans